Navigation Links
Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:4/29/2008

CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $99.0 million.

2008 Year-to-Date Business Highlights

-- Idenix reported positive data from an ongoing phase I/II study of

IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being

developed for the treatment of HIV-1. In the first dosing cohort of

this study, eight HIV-1 infected treatment-naive patients receiving 800

mg of IDX899 once-daily achieved a median reduction in plasma virus

levels of approximately 2.0 log10, or 99 percent, after seven days of

treatment. The 400 mg cohort of this study is now complete and dosing

has been initiated in the 200 mg cohort. To date, no serious adverse

events have been reported and no patients have discontinued from the

study. Data from this clinical trial have been submitted for

presentation at scientific meetings this summer.

-- The company continued to make progress with its hepatitis C discovery

and development programs, having presented data from preclinical

studies of its lead nucleotide prodrug candidate, IDX184, and potential

clinical candidates from its protease inhibitor program at the annual

meeting of the European Association for the Study of the Liver (EASL)

last week. (Please see Idenix press releas
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
2. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... chemo can help avoid treatment toxicity, research shows , ... with immunodeficiencies, researchers may have found a better way ... stem-cell transplants. , A regimen using antibodies instead ... children, according to Dr. Persis J. Amrolia, a doctor ...
... TALLAHASSEE, Fla., Sept. 2 Pharmavite, a global leader in ... to test the impact of shopper education on retail purchasing of ... number of retail stores for a ninety-day trial period, LearnSomething,s ShopperAssist(TM) ... an LCD screen with ten user selectable buttons, shoppers will be ...
... , , THE WOODLANDS, Texas, Sept. 2 ... of America,s fastest-growing private companies - the Inc. 500. Inc. ... the top quarter as #117 with a three-year sales growth of 1,424%. ... are going to change the world, look at the Inc. 500," said ...
... Danaher Corporation (NYSE: DHR ) today announced that ... MDS; NYSE: MDZ ) to acquire the Analytical ... in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass ... Molecular Devices Corporation, a bioresearch and analytical instrumentation company. ...
... , , PRINCETON, N.J., ... of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with ... version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral ... oral liquid were $70 million (IMS - MAT: June 2009). ...
... , CINCINNATI, Sept. 2 LCA-Vision Inc. (Nasdaq: ... Lasik Plus ((R)) brand, today announced that members of its executive management ... , FTN Equity Capital Markets Corp. ... 2 at the Grand Hyatt Hotel in New York City; , ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 2Health News:Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 3Health News:eCardio Included on Inc. Magazine's 28th Annual List of America's Fastest-Growing Private Companies -- the Inc. 500 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:LCA-Vision to Present at September Investment Conferences 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: